Clinical Trials
3 trialsNCT07139951 2025-12-31
HORIZON
Mayo Clinic
Phase 2 Enrolling by invitation
NCT06303583 2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2 Enrolling by invitation
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation